Natesto: Nasal Testosterone Gel

If you're a younger man with low testosterone — one who might want children someday — most TRT options put you in an uncomfortable spot. Injections, transdermal gels, and pellets all work, but they tend to suppress the gonadotropins (LH and FSH) that keep your testes running. Natesto: Nasal Testosterone Gel works differently. It's the only FDA-approved intranasal testosterone product on the market, and the clinical data suggests it suppresses those hormones significantly less than the alternatives.

Quick answer: Natesto is a prescription nasal gel that delivers 11 mg of testosterone per dose (5.5 mg per nostril), applied three times daily, for a total of 33 mg/day. In the pivotal 306-patient trial, 73% of men reached normal testosterone levels at 90 days (Rogol et al., 2016). A follow-up fertility study found 81.8% of men maintained FSH in the normal range and 72.7% maintained LH in the normal range at six months — a gonadotropin-preservation profile no injection or transdermal gel can match (Ramasamy et al., 2020).

---

What Is Natesto and How Does It Differ From Other TRT?

Natesto is a prescription nasal testosterone gel — the only testosterone product FDA-approved for intranasal delivery — and it works differently from injections or topical gels because its short half-life leaves the HPG axis enough room to keep functioning. Most testosterone replacement options work by flooding your system with exogenous testosterone and letting the body handle the rest. The problem: when testosterone rises from an outside source, the hypothalamus senses it, signals the pituitary to cut LH and FSH production, and the testes stop doing their job. That's the HPG axis shutting down — and it's why conventional TRT is essentially a contraceptive for most men.

Natesto takes a different approach — not because it's a different molecule, but because of how it's delivered and how quickly it clears. It uses a short-acting intranasal formulation absorbed through the nasal mucosa, creating brief peaks rather than the sustained high levels produced by injectable testosterone cypionate or daily transdermal gels. That short half-life appears to leave enough room in the hypothalamic-pituitary feedback cycle that the testes don't fully shut down.

It's also the only testosterone product approved for nasal administration. NDA205488, issued by the FDA and held by Acerus Pharmaceuticals Corporation, covers Natesto specifically — there is no generic, and no other brand occupies this route.

For men without fertility concerns, the delivery method also eliminates the secondary transfer risk that comes with topical gels. You dose inside your nostrils, not on skin surfaces your partner or children might touch.

---

How Does Natesto Work? Mechanism and Dosing

Each Natesto dose delivers 11 mg of testosterone (5.5 mg per nostril) via 125 µL of 4.5% nasal gel, applied three times daily for a total of 33 mg/day — a dosing pattern that mimics physiologic testosterone pulses rather than the sustained depot levels produced by injections or daily gels (Rogol et al., 2016).

That TID schedule is one of the things that distinguishes it from alternatives. Daily topical gels sit on the skin and maintain sustained levels. Biweekly injections create well-documented peak-and-trough cycles. Natesto doses more like your testes once did — small pulses throughout the day — and the absorption through the nasal mucosa is rapid, with levels rising quickly after each dose before clearing between doses.

The FDA-approved target range is 300–1050 ng/dL serum total testosterone. The dose can be titrated by your provider based on morning testosterone levels drawn before the day's first dose.

From a practical standpoint: you apply Natesto approximately every 6–8 hours. You don't have to be rigid about the exact spacing, but spreading three doses through your waking hours — morning, midday, evening — is the typical pattern. The dispenser is a multi-dose pump, not a single-use applicator.

The FDA label restricts Natesto from being used alongside other intranasally administered drugs — the one exception is sympathomimetic decongestants like oxymetazoline. Other nasal medications may alter absorption.

For men with chronic nasal conditions — rhinitis, polyps, deviated septum, or significant sinusitis — Natesto is not the right choice. The FDA label explicitly notes that altered nasal anatomy or chronic nasal pathology can impair delivery and affect absorption.

---

Does Natesto Preserve Fertility and Gonadotropins?

The fertility data is where Natesto separates itself from every other TRT option — and the answer is meaningfully better than what the alternatives offer.

The key study here is Ramasamy et al. (2020), a single-center, open-label trial at the University of Miami that enrolled 60 men aged 18–55 with symptomatic hypogonadism. All had baseline total motile sperm count above 5 million — a prerequisite — and all were treated with Natesto 11 mg TID for 6 months. At six months, 90.9% of men maintained normal testosterone levels, 81.8% maintained FSH in the normal range, and 72.7% maintained LH in the normal range (Ramasamy et al., 2020).

Those numbers matter because FSH and LH are what drive spermatogenesis. When they go to zero — as commonly happens on injectable or transdermal TRT — the testes stop producing sperm. When they stay in range, spermatogenesis has a chance to continue.

The mechanistic explanation for why Natesto performs differently from longer-acting formulations comes from a systematic review by Masterson et al. (2021) that compared gonadotropin suppression across TRT delivery types. Short-acting formulations dosed multiple times daily — the category Natesto falls into — suppress FSH and LH significantly less than injectable or transdermal alternatives. The reason is pharmacokinetic: continuous high-level testosterone exposure drives persistent HPG suppression; intermittent peaks with clearance between doses allow partial recovery.

A second line of evidence involves intratesticular testosterone. Diaz et al. (2023) compared intratesticular testosterone (using 17-hydroxyprogesterone as a validated surrogate) across men receiving intranasal testosterone, intramuscular testosterone cypionate, or subcutaneous pellets. The intranasal group had a different ITT profile — supporting the idea that the nasal route preserves testicular function in ways that depot formulations do not (Diaz et al., 2023).

The clinical trial for Natesto fertility outcomes (NCT03203681) was a completed Phase 4 study specifically designed to assess LH, FSH, and semen parameters on Natesto — and its results anchor the Ramasamy et al. (2020) publication.

For a man in his 30s who has low testosterone but hasn't completed his family, this is the most important part of the Natesto story. Conventional TRT is a contraceptive. Natesto may not be — though it should still be used with appropriate monitoring and under physician guidance.

---

Does Natesto Actually Raise Testosterone Effectively?

Yes — in the pivotal 306-patient RCT (Rogol et al., 2016), 73% of men on the approved TID dose reached eugonadal testosterone (≥300 ng/dL) at Day 90 (95% CI: 68–79%), with a per-protocol rate of 76%. The trial ran at 39 US outpatient sites, included men with mean age 54.4 years and baseline testosterone below 300 ng/dL, and extended to 1 year for safety follow-up.

The trial compared two dosing arms: 228 men in the BID arm (22 mg/day) and 78 in the TID arm (33 mg/day — the approved regimen). The 73% ITT figure is a real-world number that included men who didn't titrate perfectly; the 76% per-protocol rate reflects those who completed the protocol as designed.

The study went on to a 1-year safety extension, and those data supported a consistent safety profile over longer use.

Gronski et al. (2019) stratified the same phase 3 data by baseline testosterone level and found that efficacy held even in men with very low baseline testosterone (under 100 ng/dL) — meaning the nasal route isn't limited to men who are only mildly deficient (Gronski et al., 2019).

What about allergic rhinitis? A legitimate question, since many patients have seasonal allergies and the nose is the delivery route. Rogol et al. (2018) addressed this directly with a Phase 1 pharmacokinetic crossover study in 18 eugonadal subjects with allergic rhinitis, tested under asymptomatic, symptomatic-untreated, and symptomatic-treated (oxymetazoline) conditions. The PK analysis showed no clinically meaningful difference in testosterone absorption rate or extent across conditions — meaning symptomatic allergies don't necessarily block the therapy from working (Rogol et al., 2018).

---

Safety Profile: Nasal Side Effects and the Hematocrit Advantage

Natesto's safety profile splits cleanly into two categories: local nasal effects from the delivery route, and systemic effects — where the short-acting intranasal formulation shows a meaningful advantage over depot testosterone on hematocrit.

Nasal Side Effects

The most common adverse events with Natesto are local — and unsurprising given the route. Per the FDA label, adverse reactions occurring in 3% or more of patients include: PSA increase, headache, rhinorrhea (runny nose), epistaxis (nosebleeds), nasal discomfort, nasopharyngitis, bronchitis, upper respiratory tract infection, sinusitis, and nasal scabs.

These aren't trivial, but they're also not in the same category as the systemic risks associated with higher-dose depot formulations. Most nasal side effects are mild and improve with time or proper technique. Inserting the tip of the applicator straight rather than angled toward the septum, not sniffing vigorously after application, and alternating nostrils carefully all reduce irritation.

If you have an active upper respiratory infection, that's a sensible time to pause and check with your provider. And as mentioned — if you have a structural nasal issue, Natesto is likely not appropriate.

The Hematocrit Advantage

The hematocrit data rarely gets the attention it deserves in TRT discussions — but for men already trending toward the upper end of normal, it's one of the most practical reasons to consider Natesto.

Polycythemia — elevated hematocrit from erythropoietic stimulation by testosterone — is one of the most common reasons men on conventional TRT need dose adjustments, phlebotomy, or to switch formulations. Injections, particularly testosterone cypionate at standard biweekly doses, produce sustained high testosterone levels that drive this erythropoiesis more aggressively.

Rivero et al. (2023) conducted a 2-arm, open-label, randomized trial at the University of Miami that directly compared hematocrit changes in 81 men treated with either intranasal testosterone 11 mg TID or IM testosterone cypionate 200 mg every 2 weeks. Baseline hematocrit was 44.4% in the intranasal group and 42.7% in the IM group. The primary outcome — change in hematocrit after 4 months — showed significantly less increase in the intranasal arm compared to the IM arm (Rivero et al., 2023).

A separate matched-cohort retrospective analysis (Ory et al., 2023) found that men with hypogonadism on intranasal testosterone were less likely to develop polycythemia compared to those on IM testosterone cypionate — a finding that supports the RCT data with a real-world population (Ory et al., 2023).

Another matched-cohort analysis by Reddy et al. (2023) compared secondary erythrocytosis rates across intranasal, intramuscular, and subcutaneous pellet TRT in a cohort from January 2011 through December 2020, matched 1:1:1 for age, BMI, and sleep apnea history — all confounders known to affect hematocrit (Reddy et al., 2023).

For a man who already has a hematocrit trending toward the upper end of normal, this safety profile is meaningful. It may reduce the frequency of therapeutic phlebotomy or hematology referrals relative to other delivery routes.

---

How Does Natesto Compare to Injections, Gels, and Other TRT Forms?

Natesto's primary advantage over injections and transdermal gels is gonadotropin preservation and lower hematocrit risk — at the cost of higher price, three-times-daily dosing, and no generic. For most men over 50 who aren't concerned about fertility, injections remain the standard; for younger men who are, Natesto is the only FDA-approved option with clinical fertility data.

Natesto vs. Testosterone Injections

Injections are the most studied, most effective at raising testosterone, and usually the least expensive option. But they create pronounced peaks and troughs, they suppress gonadotropins aggressively, and they produce the highest hematocrit increases of any delivery route. If you're over 50, fertility isn't a concern, and you can tolerate biweekly shots — injections remain the workhorse of TRT.

Natesto has lower peak levels, a more physiologic diurnal pattern, significantly better gonadotropin preservation, and a better hematocrit profile. The tradeoff: it costs more, requires three doses daily, and works through an unfamiliar route.

Natesto vs. Transdermal Gels (AndroGel, Testim)

Daily gels are convenient, maintain reasonably steady levels, and avoid injections. The downsides: secondary transfer risk (skin-to-skin contact can expose partners and children to testosterone), and gonadotropin suppression is still substantial with sustained daily dosing. A systematic review confirmed that shorter-acting formulations like intranasal TID suppress LH and FSH less than transdermal gels (Masterson et al., 2021).

For men living with children or partners who might contact treated skin, Natesto eliminates this concern entirely.

Natesto vs. Oral Testosterone Undecanoate (Jatenzo, Tlando)

Oral TU has become a legitimate option since FDA approval. It avoids needles and nasal application, but it requires twice-daily dosing with fat-containing meals and produces variable absorption. It doesn't have the fertility-preservation data Natesto has.

When Natesto Is the Best Fit

The clinical evidence and FDA guidance point to a clear patient profile for Natesto: men who want effective testosterone replacement while maintaining fertility potential or gonadotropin function; men who are sensitive to the secondary transfer risk of topical gels; men who prefer not to inject; and men for whom the hematocrit risk of depot formulations is a concern.

It's not the right choice for men with structural nasal conditions, men who won't comply with TID dosing, or men for whom cost is a primary barrier (Natesto is branded with no generic available).

---

Regulatory Status, WADA, and Athletic Considerations

Natesto is FDA-approved (NDA205488) for adult male hypogonadism and is a WADA S1 prohibited substance — meaning athletes who need it must obtain a Therapeutic Use Exemption before starting, not after.

FDA Approval

Natesto is FDA-approved under NDA205488 for testosterone replacement in adult males with conditions associated with a deficiency or absence of endogenous testosterone — covering both primary hypogonadism (testicular failure) and hypogonadotropic hypogonadism (pituitary or hypothalamic origin). The manufacturer is Acerus Pharmaceuticals Corporation, a Canadian company. The approved dose is exactly 11 mg (two actuations, one per nostril) three times daily.

No compounding required. This is a commercially manufactured, FDA-regulated product — not a pharmacy-compounded preparation.

WADA and Athlete Considerations

Testosterone is classified as a prohibited substance under S1: Anabolic Agents (Anabolic Androgenic Steroids) on the WADA Prohibited List — prohibited at all times, both in and out of competition. USADA follows the same classification for US athletes.

If you have a documented diagnosis of hypogonadism and compete in a WADA-governed sport, a Therapeutic Use Exemption (TUE) is the required path. You apply through your national anti-doping organization before beginning treatment. The documentation requirements are specific, and the TUE must be in place before your first dose — not retroactively.

If athletic performance or competition is part of your context, this needs to be part of the conversation with your prescribing provider before starting Natesto.

---

Who Should Consider Natesto?

In clinical practice, Natesto tends to be the right conversation for younger men — those in their 20s through early 40s — who are symptomatic but haven't completed their family, or who have a hematocrit already trending toward the upper end of normal. Based on the clinical data and FDA guidance, Natesto is worth a serious conversation if:

• You have confirmed hypogonadism (two fasting morning testosterone levels below 300 ng/dL, with symptoms) and want to preserve fertility potential or keep gonadotropins functional
• You haven't completed your family and want to avoid suppressing the HPG axis
• You want to avoid secondary testosterone transfer to partners or children
• You have a hematocrit that's already trending high, or polycythemia is a concern in your history
• You'd rather apply something three times daily than inject biweekly

Natesto is probably not the right fit if you have chronic sinusitis, nasal polyps, a significantly deviated septum, or another structural issue that would impair nasal delivery. It also requires honest compliance with three-times-daily dosing — missing doses more often than occasionally will undercut the therapy's effectiveness.

To explore how Natesto fits into a broader hormone optimization plan — or to run the labs that establish whether TRT is even indicated — consider working with a provider who starts with data, not assumptions. At HEXIS, every protocol begins with a full hormone panel before any treatment decision is made.

If you're thinking about TRT broadly, it's worth reading our overview of how testosterone replacement therapy works and what the evidence says about low testosterone symptoms in men. For men who want to understand how different formulations compare, our guide to testosterone therapy options walks through each delivery route in depth.

Schedule a consultation to discuss whether Natesto or another testosterone therapy is right for your situation — based on your actual labs, not a guess.

---

Frequently Asked Questions

Does Natesto affect sperm count or fertility?

Natesto appears to suppress sperm production less than injections or transdermal gels. In a six-month trial of 33 evaluable men, 81.8% maintained FSH and 72.7% maintained LH in the normal range — the gonadotropins that drive sperm production. This doesn't guarantee preserved fertility, but the profile is meaningfully better than depot TRT options. Discuss sperm banking and monitoring with your provider before starting (Ramasamy et al., 2020).

How does Natesto compare to testosterone injections?

Injections produce higher peaks, stronger gonadotropin suppression, and greater hematocrit increases than Natesto. Natesto uses three small daily doses that clear between administrations, which appears to allow partial HPG axis recovery. A randomized trial found significantly less hematocrit increase with intranasal testosterone versus IM testosterone cypionate over four months (Rivero et al., 2023). The tradeoff: injections cost less and require less frequent administration.

Can I use Natesto if I have seasonal allergies or rhinitis?

A Phase 1 study specifically tested testosterone nasal gel in subjects with allergic rhinitis under asymptomatic, symptomatic-untreated, and oxymetazoline-treated conditions. Testosterone absorption was not meaningfully affected by active allergy symptoms. However, chronic structural nasal conditions (polyps, severely deviated septum, significant sinusitis) are a different situation — those can impair delivery and are a reason to consider a different TRT route (Rogol et al., 2018).

Is Natesto less likely to cause high hematocrit than injections?

Yes, based on randomized trial data. A 2-arm RCT showed significantly less hematocrit increase in men on intranasal testosterone 11 mg TID versus IM testosterone cypionate 200 mg every two weeks over four months. A matched-cohort study confirmed lower rates of secondary erythrocytosis (polycythemia) with the intranasal route versus injections or pellets (Rivero et al., 2023; Reddy et al., 2023).

What is the correct Natesto dosing?

The FDA-approved dose is 11 mg per application — 5.5 mg per nostril, two actuations of the multi-dose pump — applied three times daily (TID) for a total of 33 mg/day. Each application delivers 125 µL per nostril. Your provider may adjust timing and monitor morning testosterone levels to confirm you're reaching the target range of 300–1050 ng/dL (Rogol et al., 2016).

---